Experienced team with excellent track record

Board members and management of Gesynta Pharma have extensive experience from leading positions in major pharmaceutical companies, as well as deep knowledge about all phases of drug development from discovery to the commercialization of approved products.
The company has presented positive study outcomes and generated a robust financial foundation for its continued value creation activities.

A solid clinical pipeline based on drug candidates with a unique mode of action

Gesynta Pharma’s drug candidates target both rare diseases as well as major diseases with large patient populations.
The high unmet medical needs addressed by the company’s drug candidates imply significant commercial potential on the global market.

A strong investor base

Gesynta Pharma has a solid financial situation. Owners include reputable institutional investors such as Industrifonden, Linc, and Hadean Ventures, as well as several successful life science industry entrepreneurs.

A solid clinical pipeline based on drug candidates with a unique mode of action

Gesynta Pharma’s drug candidates target both rare diseases as well as major diseases with large patient populations.
The high unmet medical needs addressed by the company’s drug candidates imply significant commercial potential on the global market.

Lead compound GS-248 in Phase II for systemic sclerosis

In preclinical studies, the lead drug candidate GS-248 has shown a unique ability to reduce inflammation while simultaneously dilating the body`s smallest vessels. These properties may lead to improved treatments for a number of serious diseases.
GS-248 is currently being developed as a new treatment for the rare disease systemic sclerosis and could therefore attain orphan drug designation, providing regulatory advantages.

Second-generation drug candidates with the potential to address other complex diseases

Gesynta Pharma’s next generation of pharmacological treatments present a broad range of opportunities based on unique anti-inflammatory, vasoprotective, and pain-relieving properties.
The first compound in this next generation series, GS-073, is expected to enter clinical phase I in 2022

Gesynta Pharma - Model GS-659 -Drug Candidate